Patent: 9,005,616
✉ Email this page to a colleague
Summary for Patent: 9,005,616
| Title: | Methods and compositions for the inhibition of transplant rejection |
| Abstract: | Methods for modulating immune responses in a subject are provided. A preferred embodiment provides methods and compositions for reducing or inhibiting transplant rejection in a subject, preferably a human subject. Transplant rejection can be inhibited or reduced in a subject by administering an effective amount of B7-H4 polypeptide, fragments or fusions thereof to inhibit or reduce the biological activity of an immune cell or to reduce the amounts of proinflammatory molecules at a site of transplant. Th1, Th17 and Th22 cells are exemplary T cells that can be targeted for inhibition by B7-H4 polypeptides, fusion proteins or fragments thereof to inhibit or reduce inflammation. |
| Inventor(s): | Langermann; Solomon (Baltimore, MD), Liu; Linda (Clarksville, MD) |
| Assignee: | Amplimmune, Inc. (Gaithersburg, MD) |
| Application Number: | 13/392,399 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,005,616
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bristol-myers Squibb Company | NULOJIX | belatacept | For Injection | 125288 | 06/15/2011 | ⤷ Try a Trial | 2029-08-31 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
